Stock Analiz

Recursion Pharmaceuticals, Inc. (RXRX) financials: revenue, earnings and cash flow

Fiscal 2019–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Recursion Pharmaceuticals’s revenue went from $2M in fiscal 2019 to $75M in fiscal 2025, growth of about 78.4% a year.

Net income in fiscal 2025 was -$645M, a net margin of -863.4%; the best year in this period was 2019 with -$62M.

Over the twelve months to September 30, 2026, revenue was $68M and net income -$476M.

Free cash flow was -$378M in fiscal 2025 and positive in 0 of the 7 years shown.

The diluted share count rose 1974% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2019: $2M20192020: $4M20202021: $10M20212022: $40M20222023: $45M20232024: $59M20242025: $75M2025$75M
Net income
2019: -$62M20192020: -$87M20202021: -$186M20212022: -$239M20222023: -$328M20232024: -$464M20242025: -$645M2025-$645M
Free cash flow
2019: -$61M20192020: -$51M20202021: -$198M20212022: -$121M20222023: -$300M20232024: -$373M20242025: -$378M2025-$378M
EPS (diluted)
2019: $-2.8720192020: $-3.9920202021: $-1.4920212022: $-1.3620222023: $-1.5820232024: $-1.6920242025: $-1.442025$-1.44

Income statement

Fiscal yearTTM2025202420232022202120202019
Revenue$68M$75M$59M$45M$40M$10M$4M$2M
Gross profit$20M$4M$14M$2M-$8M$10M$4M—
Operating income-$495M-$648M-$479M-$350M-$246M-$183M-$85M-$62M
Net income-$476M-$645M-$464M-$328M-$239M-$186M-$87M-$62M
EPS (diluted)$-0.86$-1.44$-1.69$-1.58$-1.36$-1.49$-3.99$-2.87
R&D$373M$475M$314M$241M$156M$135M$63M$46M
Revenue growth—+26.9%+32.0%+11.9%+291.5%+156.9%+70.9%—

Cash flow

Fiscal yearTTM2025202420232022202120202019
Operating cash flow-$311M-$372M-$359M-$288M-$84M-$159M-$45M-$57M
Capital spending-$2M-$6M-$14M-$12M-$37M-$40M-$6M-$4M
Free cash flow-$312M-$378M-$373M-$300M-$121M-$198M-$51M-$61M
Dividends paid—$0$0$0$0$0$0$0
Buybacks————————
Stock-based pay$89M$111M$82M$54M$28M$15M$4M$1M

Balance sheet

Fiscal yearTTM2025202420232022202120202019
Cash—$743M$594M$392M$550M$517M$262M$75M
Debt—$78M$108M$51M$51M$49M$12M—
Equity—$1.1B$1.0B$463M$486M$543M-$206M-$124M
Total assets—$1.5B$1.4B$654M$701M$610M$299M—
Shares (diluted)543M447M274M208M176M125M22M22M

Margins and returns

Fiscal yearTTM2025202420232022202120202019
Gross margin29.2%5.0%23.1%4.5%-21.2%100.0%100.0%—
Operating margin-725.4%-867.9%-814.1%-785.3%-616.7%-1795.8%-2135.7%-2692.6%
Net margin-697.1%-863.4%-788.0%-736.0%-601.1%-1832.2%-2196.0%-2668.3%
FCF margin-458.0%-506.5%-633.7%-672.4%-302.6%-1949.4%-1293.0%-2628.4%
ROIC—-53.6%-41.8%-67.3%-45.8%-30.9%——
ROE—-57.0%-44.8%-70.8%-49.3%-34.4%42.2%49.8%

Frequently asked questions

What is Recursion Pharmaceuticals’s annual revenue?

$75M in fiscal 2025 and $68M over the twelve months to September 30, 2026.

How much profit does Recursion Pharmaceuticals make?

Net income was -$645M in fiscal 2025 (net margin -863.4%).

Is Recursion Pharmaceuticals’s revenue growing?

Yes: revenue rose 26.9% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.